Exhibit 99.1

CENCORA, INC.

SUMMARY REPORTABLE SEGMENT INFORMATION

(in thousands)

(unaudited)

The following illustrates revised reportable segment revenue information for the periods indicated:

						Fiscal Year Ended September 30, 2026
Revenue						First Quarter						Second Quarter						Third Quarter						Fourth Quarter						Fiscal Year
						(As Revised)						(As Revised)						(As Revised)						(As Revised)						(As Revised)
Pharmaceutical Distribution and Services						$	72,969,277					$	66,108,390					$	71,164,265					$	74,242,224					$	284,484,156
Specialty Pharmaceutical and Provider Services						11,098,508						10,471,417						11,645,430						12,175,177						45,390,532
Other						2,128,947						2,055,571						2,253,330						2,302,073						8,739,921
Intersegment eliminations						(264,716)						(279,462)						(308,188)						(364,944)						(1,217,310)
Total revenue						$	85,932,016					$	78,355,916					$	84,754,837					$	88,354,530					$	337,397,299
						Fiscal Year Ended September 30, 2025
Revenue						First Quarter						Second Quarter						Third Quarter						Fourth Quarter						Fiscal Year
						(As Revised)						(As Revised)						(As Revised)						(As Revised)						(As Revised)
Pharmaceutical Distribution and Services						$	69,441,734					$	63,350,601					$	67,700,658					$	71,352,299					$	271,845,292
Specialty Pharmaceutical and Provider Services						10,490,286						10,418,900						11,136,471						10,542,389						42,588,046
Other						2,002,455						1,956,407						2,107,464						2,091,507						8,157,833
Intersegment eliminations						(447,415)						(272,235)						(281,061)						(257,641)						(1,258,352)
Total revenue						$	81,487,060					$	75,453,673					$	80,663,532					$	83,728,554					$	321,332,819

---

CENCORA, INC.

SUMMARY REPORTABLE SEGMENT INFORMATION

(in thousands)

(unaudited)

The following illustrates revised reportable segment operating income and margin information for the periods indicated:

						Fiscal Year Ended September 30, 2026
Operating income						First Quarter						Second Quarter						Third Quarter						Fourth Quarter						Fiscal Year
						(As Revised)						(As Revised)						(As Revised)						(As Revised)						(As Revised)
Pharmaceutical Distribution and Services						$	606,904					$	774,786					$	664,122					$	690,546					$	2,736,358
Specialty Pharmaceutical and Provider Services						366,582						399,311						467,908						459,221						1,693,022
Other						91,417						91,633						108,736						101,075						392,861
Intersegment eliminations						(2,189)						(2,381)						(2,680)						(1,944)						(9,194)
Total segment operating income						$	1,062,714					$	1,263,349					$	1,238,086					$	1,248,898					$	4,813,047
Percentages of revenue:
Pharmaceutical Distribution and Services
Gross profit						2.26%						2.70%						2.39%						2.31%						2.41%
Operating expenses						1.43%						1.52%						1.45%						1.38%						1.45%
Operating income						0.83%						1.17%						0.93%						0.93%						0.96%
Specialty Pharmaceutical and Provider Services
Gross profit						9.21%						12.27%						12.89%						12.58%						11.76%
Operating expenses						5.91%						8.45%						8.88%						8.81%						8.03%
Operating income						3.30%						3.81%						4.02%						3.77%						3.73%
Other
Gross profit						15.24%						15.16%						14.58%						14.30%						14.81%
Operating expenses						10.95%						10.70%						9.76%						9.91%						10.31%
Operating income						4.29%						4.46%						4.83%						4.39%						4.50%

---

CENCORA, INC.

SUMMARY REPORTABLE SEGMENT INFORMATION

(in thousands)

(unaudited)

						Fiscal Year Ended September 30, 2025
Operating income						First Quarter						Second Quarter						Third Quarter						Fourth Quarter						Fiscal Year
						(As Revised)						(As Revised)						(As Revised)						(As Revised)						(As Revised)
Pharmaceutical Distribution and Services						$	569,446					$	725,639					$	590,995					$	614,651					$	2,500,731
Specialty Pharmaceutical and Provider Services						282,531						373,741						380,246						333,989						1,370,507
Other						97,329						92,851						87,104						74,429						351,713
Intersegment eliminations						2						33						(14)						1						22
Total segment operating income						$	949,308					$	1,192,264					$	1,058,331					$	1,023,070					$	4,222,973
Percentages of revenue:
Pharmaceutical Distribution and Services
Gross profit						2.27%						2.62%						2.33%						2.28%						2.37%
Operating expenses						1.45%						1.47%						1.46%						1.42%						1.45%
Operating income						0.82%						1.15%						0.87%						0.86%						0.92%
Specialty Pharmaceutical and Provider Services
Gross profit						6.14%						9.01%						8.67%						9.23%						8.27%
Operating expenses						3.44%						5.42%						5.26%						6.07%						5.05%
Operating income						2.69%						3.59%						3.41%						3.17%						3.22%
Other
Gross profit						15.86%						16.27%						14.95%						14.57%						15.40%
Operating expenses						11.00%						11.53%						10.82%						11.01%						11.08%
Operating income						4.86%						4.75%						4.13%						3.56%						4.31%